S73 Anti‑lung cancer potential of pure esteric‑glycoside condurangogenin A against nonsmall‑cell lung

ABSTRACT

Background: Marsdenia condurango (condurango) is a tropical woody vine native to South America. Our earlier study was limited to evaluation of anti‑cancer potentials of crude condurango extract and its glycoside‑rich components in vitro on lung cancer. Objective: This study aims at evaluating the effect of the single isolated active ingredient condurangogenin A (ConA; C32H42O7) on A549, H522 and H460‑nonsmall‑cell lung cancer cells. Materials and Methods: ConA was isolated by column chromatography and analyzed by mass spectroscopy, Fourier transform infrared spectroscopy and proton‑nuclear magnetic resonance. diphenyltetrazolium bromide assays were conducted on three cell‑types using 6%‑alcohol as control. Critical studies on cellular morphology, cell‑cycle regulation, reactive oxygen species, mitochondrial membrane potential, and DNA‑damage were made, and expressions of related signaling markers studied. Results: As IC50 doses of ConA proved to be too high and toxic to both A549 and H522 cells, all experimental studies were carried out on H460 cells with the IC50 dose (32 µg/ml − 24 h). Cellular morphology revealed typical apoptotic features after ConA treatment. At early treatment hours (2 h‑12 h), maximum cells were arrested at G0/G1 phase that could be correlated with reduced level of cyclin D1‑CDK with p21 up‑regulation. At 18 h − 24 h, sub G0/G1 cell population was increased gradually, as revealed from cytochrome‑c release and caspase‑3 activation, further confirming the apoptosis‑inducing ability of ConA at later phases. Gradual increase of TUNEL‑positive cells with significant modulation of mitochondria‑dependent apoptotic markers at longer time‑points would establish apoptosis‑induction property of ConA, indicating its potential as a strong candidate for anti‑cancer drug formulation. Conclusion: Further studies are warranted against other types of cancer cells and animal models before its possible human use.

KEYWORDS

• Apoptosis
• cell cycle
• condurangogenin A
• cyclin D1‑CDK pathway
• H460‑nonsmall cell lung cancer cell
• p21/p53

Showing references and in-text citations exactly as published.

• DOI10.4103/0973-1296.157698Copy

RELATED ARTICLES

Matched on section and article type within this issue of Pharmacogn. Mag..

• Article · VOLUME 11, ISSUE 42SS1 Cytotoxic glucosphingolipid from Celtis AfricanaShagufta Perveen, Areej Mohammad Al‑Taweel, Ghada Ahmed Fawzy, Azza Muhammed El‑Shafae, Afsar Khan, Peter Proksch · pp. 1–5Original ArticleSame type: Article
• Article · VOLUME 11, ISSUE 42SCytotoxicity of some edible mushrooms extracts over liver hepatocellular carcinoma cells in conjunction with their antioxidant and antibacterial propertiesGökhan Sadi, Buğrahan Emsen, Abdullah Kaya, Aytaç Kocabaş, Seval Çınar, Deniz İrtem Kartal · pp. 6–18Original ArticleSame type: Article
• Article · VOLUME 11, ISSUE 42SS19 Pharmacophore modeling, in silico screening, molecular docking and molecular dynamics approaches for potential alpha‑delta bungarotoxin‑4 inhibitors discoveryR. Barani Kumar, M. Xavier Suresh, B. Shanmuga Priya · pp. 19–28Original ArticleSame type: Article
• Article · VOLUME 11, ISSUE 42SS29 Antimutagenic potential of harpagoside and Harpagophytum procumbens against 1‑nitropyreneLuigi Manon, Baghdikian Béatrice, Orsière Thierry, Pompili Jocelyne, Mabrouki Fathi, Ollivier Evelyne · pp. 29–36Original ArticleSame type: Article